Although DPP-4 inhibitors have been associated with mean reductions of 0.5–0.8% in HbA1c27, in the present analysis, HbA1c reductions ≥ 1% were achieved by 18–29% more patients with T2DM receiving saxagliptin 2.5 or 5 mg as an add-on to another antihyperglycaemic agent than placebo. Here, DPP4 is linked to type 2 diabetes mellitus.